Ausgabe 10/2022
Inhalt (11 Artikel)
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
María Patricia Hernández-Mitre, Steven Y. C. Tong, Justin T. Denholm, Gregory J. Dore, Asha C. Bowen, Sharon R. Lewin, Balasubramanian Venkatesh, Thomas E. Hills, Zoe McQuilten, David L. Paterson, Susan C. Morpeth, Jason A. Roberts
Clinical Pharmacokinetic Monitoring of Free Valproic Acid Levels: A Systematic Review
Kevin Lin, Vivien F. S. Cao, Charles Au, Karen Dahri
Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs
Sarah Alrubia, Jialin Mao, Yuan Chen, Jill Barber, Amin Rostami-Hodjegan
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases
Ying Fei Li, Francois Pierre Combes, Matthias Hoch, Sebastien Lorenzo, Sherwin K. B. Sy, Yu-Yun Ho
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
Vidya Perera, Grigor Abelian, Danshi Li, Zhaoqing Wang, Liping Zhang, Susan Lubin, Akintunde Bello, Bindu Murthy
Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers
Ariel Topletz-Erickson, Anthony Lee, Evelyn L. Rustia, Hao Sun, JoAl G. Mayor, Layth I. Abdulrasool, Luke Walker, Christopher J. Endres
Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling
Shixing Zhu, Jiayuan Zhang, Zhihua Lv, Peijuan Zhu, Charles Oo, Mingming Yu, Sherwin K. B. Sy
Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues
Romain Garreau, Damien Montange, Antoine Grillon, François Jehl, Tristan Ferry, Laurent Bourguignon, Sylvain Goutelle
Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis
James D. Chalmers, Helen Usansky, Christopher M. Rubino, Ariel Teper, Carlos Fernandez, Jun Zou, Kevin C. Mange
Influence of Darolutamide on Cabazitaxel Systemic Exposure
Stefan A. J. Buck, Niels A. D. Guchelaar, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Esther Oomen-de Hoop, Hans M. Westgeest, Paul Hamberg, Danielle Mathijssen-van Stein, Martijn P. Lolkema, Stijn L. W. Koolen, Ronald de Wit, Ron H. J. Mathijssen
Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases
Ying Fei Li, Francois Pierre Combes, Matthias Hoch, Sebastien Lorenzo, Sherwin K. B. Sy, Yu-Yun Ho